Ireland Asthma Treatment Market, By Treatment (Long Term Medications, Quick Relief Medications), By Route of Administration (Injectable, Oral, Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), By Region, Competition, Forecast and Opportunities 2028

Ireland asthma treatment market is expected to grow at steady rate an impressive rate during the forecast period on account of rising prevalence of asthma, increase in air pollution, rise in number of product launches, increase in number of clinical trials for better clinical and therapeutics for asthma is expected to drive the growth of Ireland asthma treatment market during the forecast period. For instance, according to Center for Disease Control and Prevention (CDC), during the coronavirus pandemic, individuals suffering from moderate to severe asthma were at a greater risk of falling ill with acute respiratory disease. Furthermore, rising healthcare expenditure and rise in research and development is expected to bolster the growth of the Ireland asthma treatment market. These factors are actively driving the growth of the Ireland asthma treatment market in the upcoming five years, 2024-2028.

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, which results in recurring episodes of wheezing, coughing, shortness of breath, and chest tightness. It is a common condition that affects the lungs and can vary in severity from mild to severe. For some people, it became a major concern and causes difficulty in their daily activities and could result in life threatening asthma attack, which is also known as asthma exacerbation. When a person with asthma is exposed to certain triggers, such as allergens (dust mites, pollen, pet dander), respiratory infections, irritants (smoke, strong odors, air pollution), exercise, or changes in weather, the airways become inflamed. This inflammation causes the muscles surrounding the airways to tighten and the lining of the airways to produce excess mucus, leading to the characteristic symptoms of asthma.

One of the key drivers of growth in the Ireland asthma treatment market is rise in geriatric population. According to National Institute of Health, the prevalence of the four main categories of chronic diseases among adults in Ireland has been estimated to be 9.4% for asthma, 9.8% for Chronic obstructive pulmonary disease (COPD), 5.2% for diabetes, and 4.3% for Cardiovascular (CVD). Another factor driving growth in the Ireland asthma treatment market is the rising interest of different market players for new product launches. According to the National Institute of Health, approximately 470,000 people have asthma in Ireland and 6,300 people have severe asthma. The European Community Respiratory Health Survey (ECRHS) reported that Ireland has the highest prevalence of severe asthma attacks (6%) over the past 12 months among patients aged 20–44 years across Europe. Infact, the government has made healthcare a priority and has allocated significant resources to improve healthcare investment and services. This has created a favorable environment for market players, with a growing demand for developing new products and services.

Additionally, the manufacturers in the asthma treatment market are introducing new therapies and products that reduces the prevalence of life-threatening or uncontrolled asthma attack in patients. Asthma is one of the most common non-communicable diseases in children, and its prevalence varies across countries. For instance, International Study of Asthma and Allergies in Childhood (ISAAC), using a simple and inexpensive standardized methodology, has provided valuable data on the prevalence of the symptoms of childhood asthma and allergies for international comparison from countries with different socio-economic backgrounds.

Furthermore, the ongoing research and development of technology in the development of therapy for asthma treatment is expected to aid the growth of the Ireland asthma treatment market in the forecast period, 2024-2028. Moreover, the government also supports the idea by increasing investment in the pharmaceutical sector and the pharmaceutical companies to enforce manufacturers for taking interest in research and development of advanced therapies in Ireland to bolster the growth of Ireland asthma treatment market.

Rising Prevalence of Chronic Diseases

Asthma is the most common chronic disease. For instance, according to WHO, asthma affected about 262 million people and 455,000 people succumbed to the disease in 2019. Majority of asthma related deaths occur in low and lower middle-income countries where underdiagnosis and undertreatment are common. Asthma can be a persisting and recurring health problem, thus increasing the likelihood of health, social, and economic costs for the individuals, their families and on the healthcare system across the country. We can prevent from asthma by proceeding with reduced tobacco, affordable medication, long term illness scheme, DPS threshold reduction, clean outdoor air, clear outdoor air in the home. According to Asthma society of Ireland, in 2019, 890,000 people experience asthma at some stage of their life in which 380,000 people in Ireland currently have asthma.

Additionally, the increasing number of diagnosed cases and awareness of asthma contribute to the demand for effective treatment options. In Ireland, it is estimated that up to 60% of people with asthma don’t have their condition under control. For many people, this is due to the high cost of the essential controller medication which forms the core of asthma management. Controller inhalers can cost up to €70 each per month and asthma, despite being a lifelong condition, is not included in the long-term illness scheme in Ireland. As a result, these people are at risk of an asthma attack and the development of new therapies will lead to the propel the growth of Ireland asthma treatment market.

Furthermore, a higher prevalence of asthma in the population directly translates to an increased demand for asthma treatment. As more individuals are diagnosed with asthma, the need for effective treatment options rises. This creates a larger market for pharmaceutical companies and healthcare providers to cater to. With a higher prevalence of asthma, there is an increased focus on improving treatment accessibility. Healthcare providers and professionals are more likely to prioritize asthma management programs, ensuring that patients have access to appropriate medications, healthcare services, and education. This accessibility drives the growth of Ireland asthma treatment market.

Increasing Air Pollution Triggering Asthma Cases

Asthma is a chronic respiratory condition marked by fluctuating airflow restriction, bronchial hyper responsiveness, and inflammation of the airways. Air pollution appears to have a negative impact on asthma outcomes in both adults and children. For instance, according to research, the air pollution from traffic, nitrogen dioxide, and second-hand smoking (SHS) are all substantial risk factors for the development of asthma in children. Asthma symptoms, exacerbations, and decreased lung function can all be triggered by exposure to outside pollution as the outside environment is very polluted and is expected to bolster the growth of Ireland asthma treatment market.

Download Free Sample Report 

Recent Developments

In March 2023, a company namely Astra Zeneca Pharmaceuticals Ltd, Amgen’s Asthma had launched Tezspire picks up backing from England’s Nice. Tezspire won approvals in the U.K. and Europe in September 2022. The asthma biologic won an FDA endorsement in late 2021. TEZSPIRE proactively helps reduce inflammation in patients with severe asthma which provides better breathing with improved lung function.

In April 2020, EMA’s human medicines committee (CHMP) has recommended granting a marketing authorization in the European Union for Enerzair breezhaler, a new asthma treatment which includes an optional digital sensor. This is the first asthma triple combination therapy; it consists of a fixed dose combination of three active substances (indacaterol, glycopyrronium and mometasone furoate) in capsules, to be administered using an inhaler. An optional electronic sensor may also be co-packed with the product. The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient. The sensor will send the data to an app on a smart phone or other suitable device.

In July 2020, Novartis AG today announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year. Once-daily Enerzair Breezhaler is the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination available in the EU for asthma patients.

Market Segmentation

The Ireland asthma treatment market is segmented by treatment, route of administration, distribution channel, regional distribution, and competitional landscape. Based on treatment, the market is further bifurcated into long term medications and quick relief medications. Based on route of administration, the market is bifurcated into injectable, oral, and inhaled. Based on distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

Market Players

AstraZeneca Pharmaceuticals Ireland, Fresenius Kabi Ireland, GlaxoSmithKline Ireland, Teva Pharmaceuticals Ireland Limited, Novartis Ireland Limited, Sanofi Aventis Ireland Ltd, Hoffmann-La Roche Ireland Limited, Regeneron Ireland, and Merck & Co. Ireland Limited are some of the leading companies operating in the Ireland asthma treatment market.

Report Scope:

In this report, Ireland asthma treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Ireland Asthma Treatment Market, By Treatment:

o   Long Term Medications

o   Quick Relief Medications

• Ireland Asthma Treatment Market, By Route of Administration:

o   Injectable

o   Oral

o   Inhaled

• Ireland Asthma Treatment Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies & Drug Stores

o   Online Pharmacies

• Ireland Asthma Treatment Market, By Region:

o   Northern Ireland

o   North-West

o   West

o   Midland East

o   Dublin

o   Shannon

o   South-East

o   Cork-Kerry

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Ireland asthma treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

It is an upcoming report to be released soon. If you wish and early delivery of this report or want to confirm the date of release, please contact us at [email protected]